Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …

Infections due to carbapenem-resistant Enterobacteriaceae (CRE) are increasingly
prevalent in children and are associated with poor clinical outcomes. Optimal treatment …

Scope These ESCMID guidelines address the targeted antibiotic treatment of third-
generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem …

Ceftazidime-avibactam was used to treat 77 patients with carbapenem-resistant
Enterobacteriaceae (CRE) infections at our center. Thirty-and 90-day survival rates were …

Background Bloodstream infections (BSI) caused by carbapenem-resistant K. pneumoniae
(CRKP) are associated with high rates of morbidity and mortality. Early identification of …

Objectives The primary objective was to describe clinical features, treatment and outcomes
in patients with carbapenemase-producing Enterobacteriaceae (CPE) bacteremia …

Purpose The pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity,
efficacy, safety, and current regulatory status of imipenem/cilastatin/relebactam are …

Enhanced surveillance for CREs was established at national sentinel sites in South Africa.
We aimed to apply an epidemiological and microbiological approach to characterise CREs …

CAZ-AVI and meropenem-vaborbactam seem destined to become the backbone of target
therapy for high-risk patients with severe infections caused by susceptible CRE strains …

Introduction Risk factors for carbapenemase-producing Enterobacterales (CPE)
acquisition/infection and associated clinical outcomes have been evaluated in the context of …